AI is making inroads across the entire healthcare industry — from genomic research to drug discovery, clinical trial workflows and patient care. I...
As the science of cell and gene therapies (CGT) reaches unprecedented heights, equitable access to these lifesaving treatments must keep pace, said...
CPHI Americas 2025 registration for next year’s event is now open and will include increased attendance from Latin American countries. ...
Efforts to build a new manufacturing, biomanufacturing and R&D hub in Saudi Arabia and across the wider Middle East are accelerating as...
Pfizer Inc. (NYSE: PFE) will highlight the latest advancements from its growing hematology and breast cancer portfolios at the American Society of Hematolo...
Amgen (NASDAQ:AMGN) announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheum...
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three abstracts highlighting significant adv...
- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripot...
Gilead Sciences, Inc. (Nasdaq: GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infe...
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral t...
bluebird bio, Inc. (Nasdaq: BLUE) announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...
At the American Society of Human Genetics (ASHG) Annual Meeting (Nov. 5-9, 2024), Complete Genomics, a pioneering genomic sequencing company, will highligh...
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) an...
© 2025 Biopharma Boardroom. All Rights Reserved.
